Search

Displaying results 4951 - 4960 of 10000 in total
  1. Drug

    Terguride

    go.drugbank.com/drugs/DB13399
    Experimental

    Categories: Genito Urinary System and Sex Hormones
  2. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    It is developed by MedImmune for the treatment of Allergic Rhinitis. … Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development.

  3. Drug

    Lutetium Lu 177 dotatate

    go.drugbank.com/drugs/DB13985
    ApprovedInvestigational

    Lutetium Lu 177 dotatate may also be referred to as 177Lu-DOTA-Tyr3-octreotate. … It is a first radiopharmaceutical agent to be approved for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and is indicated for adult patients with somatostatin receptor-positive GEP-NETs [L1191

  4. Drug

    XR5944

    go.drugbank.com/drugs/DB06364
    Experimental

    XR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.

  5. Drug

    Recombinant alpha 1-antitrypsin

    go.drugbank.com/drugs/DB05481
    Investigational

    kallikrein, as well as neutrophil elastase. … The proteinase/antiproteinase balance is believed to be important for maintaining healthy skin. The rAAT topical gel (Dermolastin™) is indicated for patients with atopic dermatitis and psoriasis.

  6. Drug

    Talizumab

    go.drugbank.com/drugs/DB05797
    Experimental

    TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.

  7. Drug

    AEOL-10150

    go.drugbank.com/drugs/DB05874
    Experimental

    AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.

  8. Drug

    CX501

    go.drugbank.com/drugs/DB05174
    Investigational

    It is developed by Cellerix and is in phase I of clinical trials. … Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of

  9. Drug

    Palifermin

    go.drugbank.com/drugs/DB00039
    ApprovedInvestigational

    Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.[L17933]

  10. Drug

    VIT-100

    go.drugbank.com/drugs/DB05865
    Experimental

    In preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control. … It is believed that similar effects would be seen in cells isolated from hypertrophic scars.